How many insider trades does FilingIQ track for DBVT?

FilingIQ tracks 45 Form 4 insider transactions for DBVT (DBV Technologies S.A.), covering filings from Nov 22, 2021 onwards. 1 of those were filed in the last 90 days.

Are DBVT insiders net buyers or net sellers?

Across the full Form 4 history for DBVT, 4 transactions (9%) were open-market purchases and 19 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DBVT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DBVT in?

DBV Technologies S.A. (DBVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.14B.

DBVT insider trading

Healthcare

DBV Technologies S.A. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

9% / 42%

Market cap

$1.14B

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Company website: www.dbv-technologies.com

DBVT insider activity at a glance

FilingIQ has scored 45 insider transactions for DBVT since Nov 22, 2021. The most recent filing in our index is dated Jul 29, 2026.

Across the full history, 4 open-market purchases and 19 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DBVT insider trades is 52.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DBVT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,070

UNITED THERAPEUTICS Corp

APLS 271

Apellis Pharmaceuticals, Inc.

NUVL 202

Nuvalent, Inc.

KYMR 200

Kymera Therapeutics, Inc.

HNGE 192

Hinge Health, Inc.

GH 189

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for DBVT?: FilingIQ tracks 45 Form 4 insider transactions for DBVT (DBV Technologies S.A.), covering filings from Nov 22, 2021 onwards. 1 of those were filed in the last 90 days.
Are DBVT insiders net buyers or net sellers?: Across the full Form 4 history for DBVT, 4 transactions (9%) were open-market purchases and 19 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DBVT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DBVT in?: DBV Technologies S.A. (DBVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.14B.

Methodology & sources

Every DBVT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.